Icky ipi.

A phase 1/2 trial of ipilimumab 1 mg/kg on weeks 1 and 4 of definitive chemoradiation for non-small cell lung cancer was closed to accrual early after 16 (84%) of the first 19 enrollees experienced G3+ toxicities—mostly pulmonary—including treatment related death in 5 (26%) cases. | Liveringhouse, ASTRO 2021